Amneal Pharmaceuticals (AMRX)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-10-29
$21.35+0.99%
Close 2026-10-29 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-10-29
Research Workspace
Put AMRX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Cash from operations improves from negative $26.7 million: Comparison needs review.
View ThesisRevenue is growing steadily — about 9% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, earnings delivery, margins.
View ManagementExpectations look high — the market is pricing in about 22% growth a year, above the roughly 9% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskAmneal’s lanreotide launch and Kashiv M&A need to support growth despite modest revenue growth. Revenue growth reached 10% year over year in Q2, following 4% in Q1. Q2 non-GAAP earnings per share beat estimates by 25%. AMRX trades at 23× P/E versus a 16× peer median. The market prices in more growth than our forecast. A 25% next-quarter miss probability and the premium create specific risks. Cash from operations’ comparison needs review, so pressure on that pillar is unverified. Peer multiples imply a price about 22% below where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-29. AMRX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 7 analysts currently covering AMRX (as of Oct 2026).
Based on 5 Wall Street analysts offering 12-month price targets for AMRX in the last 4 months.
Continue this research
Compare AMRX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| AMRX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 8 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put AMRX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
FDA approval supports growth and revenue expansion.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $21.35
The last 12 months of price, then the range of analyst 12-month targets from today’s $21.35.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Expand through M&A with Kashiv BioSciences
FDA approval supports growth through M&A strategy.
Biosimilars align with M&A growth strategy.
Advances: Raise full-year 2026 financial guidance
Q2 earnings call confirms raised full-year 2026 guidance.
Advances: Improve operating income
Record revenue supports improvement in operating income.
Advances: Expand through M&A with Kashiv BioSciences
CREXONT gains support growth through M&A strategy.
Advances: Expand through M&A with Kashiv BioSciences
CREXONT gains support growth through M&A strategy.
Advances: Expand through M&A with Kashiv BioSciences
Biosimilars and patches align with growth expansion goals.